U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07658924) titled 'Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma' on June 16.
Brief Summary: Background:
CTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching. Currently, topical corticosteroids are commonly used for early-stage disease, but long-term application can cause significant skin side effects such as atrophy. Benvitimod is a novel, non-steroidal aryl hydrocarbon receptor (AhR) agonist. Previous studies suggest it has the potential to inhibit tumor cell proliferation and reduce skin inflammation, providing a promising new targeted therapy for CTCL ...